A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. - Fiedler W; Chromik J; Amberg S; Kebenko M; Thol F; Schlipfenbacher V; Christine Wilke A; Modemann F; Janning M; Serve H; Ganser A; Bokemeyer C; et al. (British journal of haematology, 2020)